Beacon Therapeutics Secures $170 Million to Advance Retinal Gene Therapies
For individuals and families navigating the challenges of inherited retinal diseases (IRDs), news of significant investment in gene therapy research offers a beacon of hope. Beacon Therapeutics, a company dedicated to developing gene therapies for blinding retinal conditions, recently announced a substantial Series B funding round, raising $170 million. This capital infusion is a crucial step forward, signaling continued progress in the quest for treatments that could preserve and restore vision for many in the IRD community.
This latest funding round brings Beacon Therapeutics' total raised capital to $290 million since its launch in 2023. The $170 million Series B was led by Forbion, a European life sciences growth fund, with participation from existing investors Syncona and Oxford Science Enterprises, as well as new investors TCGX and Advent Life Sciences. The company, headquartered in the UK with a base in Massachusetts, aims to develop a new generation of gene therapies for retinal diseases that cause blindness.
A primary focus for these newly acquired funds is the continued development of Beacon's lead asset, AGTC-501 (also referred to as laru-zova), which is currently in a Phase 2/3 clinical trial for X-linked retinitis pigmentosa (XLRP). XLRP is an inherited condition that affects approximately one in 40,000 people globally, often leading to night blindness in childhood and legal blindness by early adulthood. AGTC-501 is designed to express the full-length RPGR protein, aiming to address all photoreceptor damage, including both rod and cone loss, caused by XLRP. The first patient in the VISTA study (the Phase 2/3 trial) was dosed last month, and efficacy results are anticipated in 2026. This gene therapy has already shown promising efficacy and safety data in previous Phase 1/2 and Phase 2 trials.
Beyond XLRP, part of the $170 million will also be allocated to initiate a Phase 1/2 trial for Beacon's program targeting dry age-related macular degeneration (AMD). Dry AMD is a leading cause of irreversible vision loss in individuals over 60, for which there are currently no approved treatments. Beacon's pipeline also includes a preclinical program for cone-rod dystrophy (CRD).
For patients and families affected by IRDs, this significant investment represents a commitment to accelerating research and development in a field where unmet needs are substantial. The progression of AGTC-501 through late-stage clinical trials for XLRP, and the initiation of studies for dry AMD, could potentially lead to new therapeutic options for conditions that currently have limited or no treatments. While the journey from clinical trial to approved therapy is long, each funding milestone brings the community closer to potential breakthroughs.
Beacon Therapeutics CEO David Fellows stated that the company is